Key facts
- This page summarizes Richard Afable's Form 4 filing for ACELRX PHARMACEUTICALS INC (TLPH).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 13 Dec 2023, 16:34.
Richard Afable - 10 Oct 2023 Form 4 Insider Report for ACELRX PHARMACEUTICALS INC (TLPH)
- Reporting relationship
- Director
- Issuer ticker
- TLPH
- Reported as of
- 10 Oct 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 13 Dec 2023, 16:34:24 UTC
- Prior SEC filing
- 15 Jul 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Martha Adler, Attorney-In-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Richard Afable filed Form 4 for ACELRX PHARMACEUTICALS INC (TLPH) on 13 Dec 2023.
Change
- Previous filing in this sequence was filed on 15 Jul 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ACRX
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +581
- Change %
- +31%
- Price
- $0.000000
- Shares after
- 2,468
- Date
- 10 Oct 2023
- Ownership
- Direct
- Footnotes
- F1, F2, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ACRX
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +3,487
- Change %
- Price
- $0.000000
- Shares after
- 3,487
- Date
- 10 Oct 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,487
- Exercise price
- $0.6840
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
Footnote F2
100% of the restricted stock units shall vest on the first anniversary of the grant date, subject to Reporting Person's continuous service to the Company.
Footnote F3
Effective on October 25, 2022, the issuer effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.
Footnote F4
100% of the option shares subject to the option shall vest on the first anniversary of the grant date, subject to Reporting Person's continuous service to the Company.